ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Navidea Biopharmaceuticals, Inc." (NAVB) Report Updated: Nov 17, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Navidea Biopharmaceuticals, Inc." (NAVB)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: ENTA, GILD, FOLD, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: C down no change
Last Week: C same upgrade
Two Weeks Ago: D up no change
service keys

"Navidea Biopharmaceuticals, Inc."© quotemedia

Company Profile

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek, a radiopharmaceutical agent for determining the spread of solid tumor cancers into the lymphatic system; AZD4694 intended for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease; and RIGScan, a tumor antigen-specific targeting agent intended to help surgeons locate cancerous or disease-involved tissue during colorectal cancer surgeries. It has a biopharmaceutical development and supply agreement with Laureate Biopharmaceutical Services, Inc. to support manufacturing process development work, initial evaluation of the CC49 master working cell bank, and the initial steps in re-validating the clinical grade and commercial production process for a humanized version of the RIGScan antibody. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. on January 05, 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Recent News: "Navidea Biopharmaceuticals, Inc."